AXL activates YAP through the EGFR–LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma

Oncogene, Published online: 17 August 2023; doi:10.1038/s41388-023-02810-7AXL activates YAP through the EGFR–LATS1/2 axis and confers resistance to EGFR-targeted drugs in head and neck squamous cell carcinoma

Source: Oncogene - August 17, 2023 Category: Cancer & Oncology Authors: Kento Okamoto Toshinori Ando Hiroki Izumi Susumu S. Kobayashi Tomoaki Shintani J. Silvio Gutkind Souichi Yanamoto Mutsumi Miyauchi Mikihito Kajiya Source Type: research